Q3 in line with promising outlook for 2025 Large revisions as Kaktus divestment moving from '24e to ...
Redeye comments on Scandion Oncology’s Q3 2024 report, and we judge a potential partnership or simil...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 16% for the quarter...
Redeye states the report was 2% higher in sales while higher OPEX weighted on the EBITDA and EBIT re...
Redeye gives a short comment on yesterday’s news that Curasight has announced brain cancer as the fi...
Redeye comments on the Q3 report from Moberg Pharma.
Redeye comments in EG7’s Q3-results which were better than expected, driven by strong profitability ...
Redeye provides an updated view on Genovis following a Q3 report that surpassed our estimates across...
In its CMD, Vaisala outlined its strategy and updated long-term financial targets.
Higher sales growth and gross margin in Q3 EBIT +32% (lower loss) vs ABGSCe Estimates likely to be r...
Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate acco...
Net sales and EBITDA were close to our expectations in Q3 but slightly below LSEG Data & Analytics c...
Nettoomsättningen för det tredje kvartalet uppgick till 113,8 MSEK (97,5), vilket motsvarade en orga...
Organic sales decline of 7% y-o-y EBIT margin of 7.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denm...
Obducat har publicerat bolagets Q3-rapport, vilken visade på en stark exekvering under kvartalet med...
Europe recovered and FY guidance kept EBITA cut 2-4%, eyes starting to shift to 2025e Higher organic...
Redeye returns with a positive view on the back of Bredband2’s Q3 2024 report which was largely in l...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to e...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events...
